A breakthrough brain scan shows Parkinson’s drugs can misfire in the brain, helping some patients less than others. The fix?

In a breakthrough study, scientists found that silencing a single overactive enzyme in the brain reversed early damage caused ...

Stanford researchers discovered that dialing down an overactive enzyme, LRRK2, can regrow lost cellular “antennae” in key ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

Autism spectrum disorder is tied to an increased risk for Parkinson disease, even after adjusting for depression and antipsychotic/antidepressant use.

A 12-month clinical trial investigated whether a cough medicine used in Europe called Ambroxol can slow dementia in people with Parkinson’s.

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

A cough medicine used for decades in Europe called Ambroxol has shown promise for treating dementia in people with ...

Putting the brakes on an enzyme might rescue neurons that are dying due to a type of Parkinson's disease that's caused by a ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.

The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.